free IgE assay
Successful market entry for BioTeZ’ in-vitro diagnostic recoveryELISA in 2011. Especially the assay for free IgE and available omalizumab exceeds the expectations. In 2012 the research team will focus on free TNF inhibitors like adalimumab and infliximab and Galimumab.